Anna H. S.
- Country
- Germany
- Department
- Klinik und Poliklinik fuer Innere Medizin
Research Overview
- Evaluation of PXS-5505 Combined with 5-Azacitidine in Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
- Phase 2 Open‑Label Study of BMS‑986504 Monotherapy and Combination Therapy in Advanced/Metastatic Solid Tumors with Homozygous MTAP Deletion
- Phase II Evaluation of Azacitidine, Venetoclax, and Tagraxofusp in Higher-Risk Chronic Myelomonocytic Leukemia Patients
Data & Insights
Has run more than one trial at 5 of 41 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating complex blood disorders, with particular emphasis on myelodysplastic neoplasms (MDS) and chronic myelomonocytic leukemia (CMML).
- Myelodysplastic Syndromes
- Chronic Myelomonocytic Leukemia
- Higher-risk Blood Disorders
The investigator explores innovative therapeutic approaches for these challenging hematologic conditions.
Therapeutic Innovation
Working at the forefront of combination therapy development, the investigator studies novel treatment approaches for hematologic malignancies.
- Novel Agent Combinations
- Targeted Therapies
- Standard of Care Enhancement
Their work focuses on improving treatment outcomes through innovative therapeutic strategies.
Clinical Applications
The investigator develops treatment protocols for patients with advanced hematologic disorders, particularly focusing on high-risk cases.
- Treatment Response Assessment
- Safety Evaluation
- Patient Care Optimization
Their research aims to enhance therapeutic efficacy in challenging blood disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.